GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	December 31, 2025								December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,448)	$	—	$	2,272	$	10,720	$	(7,749)	$	—	$	2,971
Intangible asset – axicabtagene ciloleucel	7,110		(3,127)		—		3,983		7,110		(2,721)		—		4,389
Intangible asset – Trodelvy	11,730		(4,164)		—		7,566		11,730		(3,083)		—		8,647
Intangible asset – Hepcludex	845		(415)		—		430		845		(329)		—		516
Other	1,483		(1,056)		—		428		1,474		(940)		1		535
Total finite-lived assets	31,888		(17,211)		—		14,678		31,879		(14,822)		1		17,058
Indefinite-lived assets – IPR&D(1)	2,300		—		—		2,300		2,890		—		—		2,890
Total intangible assets	$	34,188	$	(17,211)	$	—	$	16,978	$	34,769	$	(14,822)	$	1	$	19,948

_______________________________

(1) The Indefinite-lived assets – IPR&D balance as of December 31, 2025 was comprised of $1.75 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $550 million related to bulevirtide. The balance as of December 31, 2024 was comprised of $1.75 billion related to SG for NSCLC and $1.1 billion related to bulevirtide. See “2025 Impairment” below for 2025 activity.

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	December 31, 2025								December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,448)	$	—	$	2,272	$	10,720	$	(7,749)	$	—	$	2,971
Intangible asset – axicabtagene ciloleucel	7,110		(3,127)		—		3,983		7,110		(2,721)		—		4,389
Intangible asset – Trodelvy	11,730		(4,164)		—		7,566		11,730		(3,083)		—		8,647
Intangible asset – Hepcludex	845		(415)		—		430		845		(329)		—		516
Other	1,483		(1,056)		—		428		1,474		(940)		1		535
Total finite-lived assets	31,888		(17,211)		—		14,678		31,879		(14,822)		1		17,058
Indefinite-lived assets – IPR&D(1)	2,300		—		—		2,300		2,890		—		—		2,890
Total intangible assets	$	34,188	$	(17,211)	$	—	$	16,978	$	34,769	$	(14,822)	$	1	$	19,948

_______________________________

Summary of Estimated Future Amortization Expense of Finite-Lived Intangible Assets

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2025:


(in millions)	Amount
2026	$	2,383
2027	2,380
2028	2,319
2029	1,791
2030	1,605
Thereafter	4,199
Total	$	14,678